ClearPoint Neuro (Nasdaq:CLPT) announced today that it entered into a note financing agreement with Oberland Capital Management of up to $110 million. The agreement includes $30 million in gross proceeds at closing. Oberland agreed to provide an additional $25 million at the option of the company at any time prior to Dec. 31, 2026. It […]
ClearPoint Neuro
ClearPoint Neuro launches new navigation software
ClearPoint Neuro (Nasdaq:CLPT) announced that it kicked off the full-market launch of its latest navigation software. Solana Beach, California-based ClearPoint Neuro said it commenced the full-market release of its ClearPoint Navigation Software Version 3.0. The new software introduces a new iCT image-guidance workflow option performed in a traditional operating room. ClearPoint Neuro’s new software builds […]
ClearPoint Neuro wins FDA clearance for neuro laser therapy accessory
ClearPoint Neuro (Nasdaq:CLPT) announced today that the FDA granted 510(k) clearance for its Prism bone anchor accessory. It marks the second new product introduction in 2024 for the company, with its stereotactic guidance system garnering clearance in January. The Prism system features the only non-cooled laser applicator on the market, the company said. Its next-generation laser applicator […]
ClearPoint Neuro reports positive laser therapy results
ClearPoint Neuro (Nasdaq:CLPT) today announced preclinical results highlighting the accuracy of its Prism neuro laser therapy system. The Prism system features the only non-cooled laser applicator on the market, the company said. Its next-generation laser applicator technology eliminates the need for external cooling. This simplifies setup, reduces power and ablation time and lessens imaging artifact […]
ClearPoint Neuro prices $15M offering
ClearPoint Neuro (Nasdaq:CLPT) announced today that it priced an underwritten public offering worth approximately $15 million. The company is offering 2,307,694 shares of its common stock at a price to the public of $6.50 per share. It also granted the underwriter a 30-day option to purchase up to an additional 346,154 shares of common stock […]
New ClearPoint Neuro software wins FDA clearance, used in first cases
ClearPoint Neuro (Nasdaq:CLPT) announced that the FDA cleared its ClearPoint 2.2 software with integrated Maestro Brain Modeling. The Solana Beach, California-based company also reported the first-in-human cases following the FDA clearance. ClearPoint Neuro President and CEO Joe Burnett said the system now offers fast, peri-procedural segmentation of the cortical structures of the brain. This helps […]
ClearPoint Neuro reports first procedures with laser therapy system
ClearPoint Neuro (Nasdaq:CLPT) announced that it completed the first procedures with its laser therapy and navigation systems. In September 2022, the FDA cleared the company’s Swedish partner Clinical Laserthermia Systems’ neuro laser therapy system. The Solana Beach, California-based company planned from then to commercialize the system as the Prism. ClearPoint Neuro holds exclusive global rights […]
FDA clears stereotactic guidance system from ClearPoint Neuro
ClearPoint Neuro (Nasdaq:CLPT) announced today that it received FDA 510(k) clearance for its SmartFrame OR stereotactic system. Solana Beach, California–based ClearPoint Neuro developed its SmartFrame OR system with two main components. It features the SmartFrame OR technology with the ClearPointer optical navigation wand. SmartFrame OR offers stereotactic guidance for placing and operating instruments or devices […]
ClearPoint Neuro enters drug delivery licensing deal with UCB
ClearPoint Neuro (Nasdaq:CLPT) announced today that it entered into a multi-year license agreement with UCB over gene therapy delivery. Solana Beach, California-based ClearPoint Neuro develops a therapy-enabling platform providing navigation and delivery to the brain. The licensing agreement with UCB establishes a partnership on delivery platforms for UCB’s gene therapy portfolio. Get the full story […]
ClearPoint Neuro expects at least 22% revenue growth in 2023
ClearPoint Neuro (Nasdaq:CLPT) today announced preliminary fourth-quarter revenues that came up short of Wall Street projections. Solana Beach, California-based ClearPoint Neuro expects $5.2 million in sales for the quarter ended Dec. 31, 2022. While that comes in 21% ahead of totals from the same quarter last year, it falls short of analysts’ projections of $5.8 […]
ClearPoint Neuro to commercialize FDA-cleared neuro laser
ClearPoint Neuro (Nasdaq: CLPT) announced today that the FDA has cleared its Swedish partner Clinical Laserthermia Systems’ neuro laser therapy system. The plan is for ClearPoint Neuro to commercialize the system as the ClearPoint Prism. The company has exclusive global rights to commercialize the CLS magnetic resonance (MR) guided laser interstitial thermal therapy (MRgLITT) system. […]
